EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
12.35
-0.89 (-6.72%)
At close: May 15, 2026, 4:00 PM EDT
12.31
-0.04 (-0.32%)
Pre-market: May 18, 2026, 6:02 AM EDT
EyePoint Revenue
EyePoint had revenue of $696.00K in the quarter ending March 31, 2026, a decrease of -97.15%. This brings the company's revenue in the last twelve months to $7.62M, down -86.41% year-over-year. In the year 2025, EyePoint had annual revenue of $31.37M, down -27.50%.
Revenue (ttm)
$7.62M
Revenue Growth
-86.41%
P/S Ratio
135.99
Revenue / Employee
$35,579
Employees
214
Market Cap
1.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37M | -11.90M | -27.50% |
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
| Dec 31, 2018 | 4.57M | 1.61M | 54.37% |
| Jun 30, 2018 | 2.96M | -4.58M | -60.72% |
| Jun 30, 2017 | 7.54M | 5.92M | 365.37% |
| Jun 30, 2016 | 1.62M | -24.95M | -93.90% |
| Jun 30, 2015 | 26.57M | 23.09M | 664.90% |
| Jun 30, 2014 | 3.47M | 1.33M | 62.06% |
| Jun 30, 2013 | 2.14M | -1.38M | -39.22% |
| Jun 30, 2012 | 3.53M | -1.44M | -28.98% |
| Jun 30, 2011 | 4.97M | -18.09M | -78.46% |
| Jun 30, 2010 | 23.05M | 10.89M | 89.55% |
| Jun 30, 2009 | 12.16M | 8.69M | 249.88% |
| Jun 30, 2008 | 3.48M | 1.69M | 94.73% |
| Jun 30, 2007 | 1.79M | 749.00K | 72.30% |
| Jun 30, 2006 | 1.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 360.78M |
| Phathom Pharmaceuticals | 204.89M |
| Maravai LifeSciences Holdings | 204.73M |
| Lexicon Pharmaceuticals | 69.64M |
| Zenas BioPharma | 10.00M |
| Aktis Oncology | 8.28M |
| Inventiva | 7.94M |
| DBV Technologies | 5.74M |
EYPT News
- 3 days ago - EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials - TheFly
- 3 days ago - EyePoint's late-stage eye drug trials to continue after safety panel review - Reuters
- 4 days ago - EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - GlobeNewsWire
- 11 days ago - EyePoint reports Q1 EPS (99c), consensus (81c) - TheFly
- 11 days ago - EyePoint Earnings Call Transcript: Q1 2026 - Transcripts
- 12 days ago - EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 19 days ago - EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - GlobeNewsWire
- 4 weeks ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire